Lakefront Biotherapeutics - Sponsored ADR

LKFT Healthcare Biotechnology

Lakefront Biotherapeutics - Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $1.3 billion, up 321.9% from fiscal 2024.

Revenue
−95.4%
EPS
+198.9%
Free cash flow
+18.2%

Quarter to June 2026, against a year earlier

33.39 0.17 −0.51%
Market cap
$2.2B
P/E
0.0×
Fwd P/E
−15.3×
Dividend yield
—
F-score
6/9
Altman Z
8.43
Beneish M
0.34
Dividend safety
n/a

Lakefront Biotherapeutics - Sponsored ADR (LKFT) Free cash flow

Alert me on Free cash flow

Lakefront Biotherapeutics - Sponsored ADR's free cash flow for fiscal 2025 was −$306.4M, compared with −$435.1M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$524.5M. Over the past ten years it has ranged from −$664.6M (fiscal 2021) to $3.5B (fiscal 2019); the current reading is higher than 55% of that period. Free cash flow has risen for 4 consecutive fiscal years. Lakefront Biotherapeutics - Sponsored ADR ranks 594th of 603 Biotechnology companies by free cash flow.

Free cash flow, annual

Embed this chart

Annual newest first

Period Free cash flow Change
FY2025 −$306.4M —
FY2024 −$435.1M —
FY2023 −$457.6M —
FY2022 −$565.5M —
FY2021 −$664.6M —
FY2020 −$592.4M —
FY2019 $3.5B —
FY2018 −$184.5M —
FY2017 −$174.6M —
FY2016 $259.6M —

Quarterly newest first

Period Free cash flow Change
Jun 2026 −$37.8M —
Mar 2026 −$95.5M —
Sep 2025 −$259.7M —
Jun 2025 −$131.8M —
33 more quarters

Against its own ten years

Low −$664.6M High $3.5B
Ten-year median −$306.4M
Current reading's percentile 55

Free cash flow against peers

What Free cash flow is

Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.

Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)

The full definition of Free cash flow →

More on LKFT